Hypertension and Stroke: Epidemiological Aspects and Clinical Evaluation

High Blood Pressure and Cardiovascular Prevention

Volumn 23, Issue 1, 2016, Pages 9-18

  Pistoia, Francesca ^a   Sacco, Simona ^a   Degan, Diana ^a   Tiseo, Cindy ^a   Ornello, Raffaele ^a   Carolei, Antonio ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Cerebrovascular disease; Dementia; Epidemiology; Hypertension; Stroke

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; EPROSARTAN; INDAPAMIDE; LOSARTAN; NITRENDIPINE; PERINDOPRIL; RAMIPRIL; TELMISARTAN; VALSARTAN; ANTIHYPERTENSIVE AGENT;

ANTERIOR CEREBRAL ARTERY; ANTIHYPERTENSIVE THERAPY; ARTERIOVENOUS MALFORMATION; ARTICLE; AUTOREGULATION; BASILAR ARTERY; BLOOD PRESSURE; BLOOD PRESSURE VARIABILITY; BRAIN BLOOD FLOW; BRAIN DAMAGE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN PERFUSION; CARDIOVASCULAR RISK; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CLASSIFICATION; DOPPLER ECHOGRAPHY; GRAY MATTER; GROUPS BY AGE; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; INCIDENCE; INTERNAL CAROTID ARTERY; INTRACRANIAL HYPERTENSION; LACUNAR STROKE; MAGNETIC RESONANCE ANGIOGRAPHY; MENTAL DETERIORATION; MIDDLE CEREBRAL ARTERY; MIDDLE TEMPORAL GYRUS; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROIMAGING; PAROXYSMAL ATRIAL FIBRILLATION; PARTIAL ANTERIOR CIRCULATION INFARCT; PERFUSION PRESSURE; POSTERIOR CEREBRAL ARTERY; POSTERIOR CIRCULATION INFARCT; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; SECONDARY PREVENTION; SUBARACHNOID HEMORRHAGE; SYSTOLIC BLOOD PRESSURE; TEMPORAL LOBE; TRANSIENT ISCHEMIC ATTACK; VASCULAR AMYLOIDOSIS; VASOCONSTRICTION; VASODILATATION; VERTEBRAL ARTERY; WHITE MATTER; WHITE MATTER LESION; BRAIN CIRCULATION; DRUG EFFECTS; HOMEOSTASIS; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; STROKE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CEREBROVASCULAR CIRCULATION; HOMEOSTASIS; HUMANS; HYPERTENSION; RISK ASSESSMENT; RISK FACTORS; STROKE;

EID: 84961938314     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.1007/s40292-015-0115-2     Document Type: Article

References (73)

1. Sarti C, Rastenyte D, Cepaitis Z, Tuomilehto J. International trends in mortality from stroke, 1968 to 1994. Stroke. 2000;31:1588–601.
2. Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. Lancet. 2003;362:1211–24.
3. Marini C, Baldassarre M, Russo T, De Santis F, Sacco S, Ciancarelli I, Carolei A. Burden of first-ever ischemic stroke in the oldest old: evidence from a population-based study. Neurology. 2004;62:77–81.
4. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.
5. Anand SS, Yusuf S. Stemming the global tsunami of cardiovascular disease. Lancet. 2011;377:529–32.
6. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2003;2:43–53.
7. Hollander M, Koudstaal PJ, Bots ML, Grobbee DE, Hofman A, Breteler MM. Incidence, risk, and case fatality of first ever stroke in the elderly population. The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2003;74:317–21.
8. Broderick J, Brott T, Kothari R, Miller R, Khoury J, Pancioli A, Gebel J, Mills D, Minneci L, Shukla R. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke. 1998;29:415–21.
9. Sacco RL, Boden-Albala B, Gan R, Chen X, Kargman DE, Shea S, Paik MC, Hauser WA. Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study. Am J Epidemiol. 1998;147:259–68.
10. Rosamond WD, Folsom AR, Chambless LE, Wang CH, Mcgovern PG, Howard G, Copper LS, Shahar E. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30:736–43.
11. Wolfe CD, Rudd AG, Howard R, Coshall C, Stewart J, Lawrence E, Hajat C, Hillen T. Incidence and case fatality rates of stroke subtypes in a multiethnic population: the South London Stroke Register. J Neurol Neurosurg Psychiatry. 2002;72:211–6.
12. Carolei A, Sacco A, De Santis F, Marini C. Epidemiology of stroke. Clin Exp Hypertens. 2002;24:479–83.
13. Feigin VL, Wiebers DO, Nikitin YP, O’Fallon WM, Whisnant JP. Stroke epidemiology in Novosibirsk, Russia: a population-based study. Mayo Clin Proc. 1995;70:847–52.
14. Mihalka L, Smolanka V, Bulecza B, Mulesa S, Bereczki D. A population study of stroke in West Ukraine: incidence, stroke services, and 30-day case fatality. Stroke. 2001;32:2227–31.
15. Morikawa Y, Nakagawa H, Naruse Y, Nishijo M, Miura K, Tabata M, Hirokawa W, Kagamimori S, Honda M, Yoshita K, Hayashi K. Trends in stroke incidence and acute case fatality in a Japanese rural area: the Oyabe study. Stroke. 2000;31:1583–7.
16. Carolei A, Marini C, Di Napoli M, Di Gianfilippo G, Santalucia P, Baldassarre M, De Matteis G, di Orio F. High stroke incidence in the prospective community-based L’Aquila registry (1994–1998): first year’s results. Stroke. 1997;28:2500–6.
17. Malmivaara A, Meretoja A, Peltola M, Numerato D, Heijink R, Engelfriet P, Wild SH, Belicza É, Bereczki D, Medin E, Goude F, Boncoraglio G, Tatlisumak T, Seppälä T, Häkkinen U. Comparing ischaemic stroke in six European countries. The EuroHOPE register study. Eur J Neurol. 2015;22:284–91.
18. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009;8:355–69.
19. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347–60.
20. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, for the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.
21. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ, Mondo C, Damasceno A, Lopez-Jaramillo P, Hankey GJ, Dans AL, Yusoff K, Truelsen T, Diener HC, Sacco RL, Ryglewicz D, Czlonkowska A, Weimar C, Wang X, Yusuf S, for the INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112–23.
22. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23.
23. Cipolla MJ. The cerebral circulation. Control of cerebral blood flow, Chapter 5. San Rafael: Morgan & Claypool Life Sciences; 2009.
24. Busija DW, Heistad DD. Factors involved in the physiological regulation of the cerebral circulation. Rev Physiol Biochem Pharamacol. 1984;101:161–211.
25. Talman WT, Dragon DN. Neuronal nitric oxide mediates cerebral vasodilatation during acute hypertension. Brain Res. 2007;1139:126–32.
26. Paulson OB, Strandgaard S, Edvinsson L. Cerebral autoregulation. Cerebrovasc Brain Metab Rev. 1990;2:161–92.
27. Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, Hatsukami TS, Higashida RT, Johnston SC, Kidwell CS, Lutsep HL, Miller E, Sacco RL, American Heart Association, American Stroke Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Nursing, Interdisciplinary Council on Peripheral Vascular Disease. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009;40:2276–93.
28. Carolei A, Pistoia F, Sacco S, Mohr JP. Temporary is not always benign: similarities and differences between transient ischemic attack and angina. Mayo Clin Proc. 2013;88:708–19.
29. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35–41.
30. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521–6.
31. Caplan LR. Lacunar infarction and small vessel disease: pathology and pathophysiology. J Stroke. 2015;17(1):2–6.
32. Sacco S, Marini C, Totaro R, Russo T, Cerone D, Carolei A. A population-based study of the incidence and prognosis of lacunar stroke. Neurology. 2006;66:1335–8.
33. Sandset EC, Jusufovic M, Sandset PM, Bath PM, Berge E, for the SCAST Study Group. Effects of blood pressure-lowering treatment in different subtypes of acute ischemic stroke. Stroke. 2015;46:877–9.
34. Xu J, Liu L, Wang Y, Zhao X, Wang C, Wang A, Wang Y. TOAST subtypes: its influence upon doctors’ decisions of antihypertensive prescription at discharge for ischemic stroke patients. Patient Prefer Adherence. 2012;6:911–4.
35. Meretoja A, Strbian D, Putaala J, Curtze S, Haapaniemi E, Mustanoja S, Sairanen T, Satopää J, Silvennoinen H, Niemelä M, Kaste M, Tatlisumak T. SMASH-U: a proposal for etiologic classification of intracerebral hemorrhage. Stroke. 2012;43:2592–7.
36. Yeh SJ, Tang SC, Tsai LK, Jeng JS. Pathogenetical subtypes of recurrent intracerebral hemorrhage: designations by SMASH-U classification system. Stroke. 2014;45:2636–42.
37. Romero JR, Pikula A, Nguyen TN, Nien YL, Norbash A, Babikian VL. Cerebral collateral circulation in carotid artery disease. Curr Cardiol Rev. 2009;5:279–88.
38. Liebeskind DS. Collateral circulation. Stroke. 2003;34:2279–84.
39. Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, Haley EC, Grotta J, Marler J. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke. 1994;25:2220–6.
40. Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, Creager MA, Eckel RH, Elkind MS, Fornage M, Goldstein LB, Greenberg SM, Horvath SE, Iadecola C, Jauch EC, Moore WS, Wilson JA, American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Functional Genomics and Translational Biology, Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:3754–832.
41. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA, American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160–236.
42. Hemphill JC 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung GL, Goldstein JN, Macdonald RL, Mitchell PH, Scott PA, Selim MH, Woo D. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46(7):2032–60.
43. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators, Gueyffier F, Boissel JP, Boutitie F, Pocock S, Coope J, Cutler J, Ekbom T, Fagard R, Friedman L, Kerlikowske K, Perry M, Prineas R, Schron E. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. Stroke. 1997;28:2557–62.
44. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke. 2003;34:2741–8.
45. Lawes CMM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke. 2004;35:1024–33.
46. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.
47. Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S, for the HOPE/HOPE-TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation. 2005;112:1339–46.
48. Chapman N, Huxley R, Anderson C, Bousser MG, Chalmers J, Colman S, Davis S, Donnan G, MacMahon S, Neal B, Warlow C, Woodward M, for the PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: The PROGRESS Trial. Stroke. 2004;35:116–21.
49. Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC, for the MOSES Study Group. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218–26.
50. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–31.
51. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:2049–51.
52. Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012;59:1110–7.
53. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J, for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–906.
54. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C, for the ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.
55. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA, for the ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204–13.
56. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, for the Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174–83.
57. Jennings GL. Recent clinical trials of hypertension management. Hypertension. 2013;62:3–7.
58. Pringle E, Phillips C, Thijs L, Davidson C, Staessen JA, de Leeuw PW, Jaaskivi M, Nachev C, Parati G, O’Brien ET, Tuomilehto J, Webster J, Bulpitt CJ, Fagard RH, for the Syst-Eur investigators. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens. 2003;21:2251–7.
59. Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Björklund-Bodegård K, Richart T, Ohkubo T, Kuznetsova T, Torp-Pedersen C, Lind L, Ibsen H, Imai Y, Wang J, Sandoya E, O’Brien E, Staessen JA, International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO) investigators. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007;370:1219–29.
60. Hansen TW, Thijs L, Li Y, Boggia J, Kikuya M, Björklund-Bodegård K, Richart T, Ohkubo T, Jeppesen J, Torp-Pedersen C, Dolan E, Kuznetsova T, Stolarz-Skrzypek K, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Lind L, Sandoya E, Kawecka-Jaszcz K, Imai Y, Wang J, Ibsen H, O’Brien E, Staessen JA, International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes Investigators. Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension. 2010;55:1049–57.
61. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895–905.
62. Aslanyan S, Fazekas F, Weir CJ, Horner S, Lees KR, for the GAIN International Steering Committee and Investigators. Effect of blood pressure during the acute period of ischemic stroke on stroke outcome: a tertiary analysis of the GAIN International Trial. Stroke. 2003;34:2420–5.
63. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010;375:906–15.
64. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, Poulter NR, Sever PS, for the ASCOT-BPLA and MRC Trial Investigators. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9:469–80.
65. Sacco S, Di Gianfilippo G, Di Napoli M, Santalucia P, Euforbio M, Triggiani L, Cimini N, Ciancarelli I, De Santis F, Olivieri L, Pistoia F, Marini C, Carolei A. Stroke in Italy: five-year results of the L’Aquila stroke registry (1994–1998) and comparison with comparable national and international population studies. Riv Ital di Neurobiol. 2006;2:109–36.
66. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, for the LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004–10.
67. Bang CN, Devereux RB, Okin PM. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction—a LIFE review. J Electrocardiol. 2014;47:630–5.
68. Maillard P, Seshadri S, Beiser A, Himali JJ, Au R, Fletcher E, Carmichael O, Wolf PA, DeCarli C. Effects of systolic blood pressure on white-matter integrity in young adults in the Framingham Heart Study: a cross-sectional study. Lancet Neurol. 2012;11:1039–47.
69. Scuteri A. Brain injury as end-organ damage in hypertension. Lancet Neurol. 2012;11:1015–7.
70. Raz N, Rodrigue KM, Kennedy KM, Acker JD. Vascular health and longitudinal changes in brain and cognition in middle-aged and older adults. Neuropsychology. 2007;21:149–57.
71. Au R, Massaro JM, Wolf PA, Young ME, Beiser A, Seshadri S, D’Agostino RB, De Carli C. Association of white matter hyperintensity volume with decreased cognitive functioning: the Framingham Heart Study. Arch Neurol. 2006;63:246–50.
72. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4:487–99.
73. Matsumoto A, Satoh M, Kikuya M, Ohkubo T, Hirano M, Inoue R, Hashimoto T, Hara A, Hirose T, Obara T, Metoki H, Asayama K, Hosokawa A, Totsune K, Hoshi H, Hosokawa T, Sato H, Imai Y. Day-to-day variability in home blood pressure is associated with cognitive decline: the Ohasama study. Hypertension. 2014;63:1333–8.